These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial. Cartenì G, Bordonaro R, Giotta F, Lorusso V, Scalone S, Vinaccia V, Rondena R, Amadori D. Oncologist; 2006; 11(7):841-8. PubMed ID: 16880243 [Abstract] [Full Text] [Related]
4. A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases. Berenson JR, Vescio RA, Rosen LS, VonTeichert JM, Woo M, Swift R, Savage A, Givant E, Hupkes M, Harvey H, Lipton A. Clin Cancer Res; 2001 Mar; 7(3):478-85. PubMed ID: 11297237 [Abstract] [Full Text] [Related]
5. Zoledronic acid-induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases. Patel K, Brahmbhatt V, Ramu V. Tenn Med; 2005 Feb; 98(2):83-5, 89. PubMed ID: 15779196 [Abstract] [Full Text] [Related]
8. Risk factors for symptomatic hypocalcaemia complicating treatment with zoledronic acid. Chennuru S, Koduri J, Baumann MA. Intern Med J; 2008 Aug; 38(8):635-7. PubMed ID: 18284458 [Abstract] [Full Text] [Related]
9. Hypocalcaemia in patients with metastatic bone disease treated with denosumab. Body JJ, Bone HG, de Boer RH, Stopeck A, Van Poznak C, Damião R, Fizazi K, Henry DH, Ibrahim T, Lipton A, Saad F, Shore N, Takano T, Shaywitz AJ, Wang H, Bracco OL, Braun A, Kostenuik PJ. Eur J Cancer; 2015 Sep; 51(13):1812-21. PubMed ID: 26093811 [Abstract] [Full Text] [Related]
11. Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases. Polascik TJ, Given RW, Metzger C, Julian SR, Vestal JC, Karlin GS, Barkley CS, Bilhartz DL, McWhorter LT, Lacerna LV. Urology; 2005 Nov; 66(5):1054-9. PubMed ID: 16286123 [Abstract] [Full Text] [Related]
12. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Musto P, Petrucci MT, Bringhen S, Guglielmelli T, Caravita T, Bongarzoni V, Andriani A, D'Arena G, Balleari E, Pietrantuono G, Boccadoro M, Palumbo A, GIMEMA (Italian Group for Adult Hematologic Diseases)/Multiple Myeloma Working Party and the Italian Myeloma Network. Cancer; 2008 Oct 01; 113(7):1588-95. PubMed ID: 18683218 [Abstract] [Full Text] [Related]
13. Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid. Pectasides D, Nikolaou M, Farmakis D, Kanakis I, Gaglia A, Kountourakis P, Karamanos NK, Economopoulos T, Raptis SA. Anticancer Res; 2005 Oct 01; 25(2B):1457-63. PubMed ID: 15865105 [Abstract] [Full Text] [Related]
14. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Lipton A, Zheng M, Seaman J. Cancer; 2003 Sep 01; 98(5):962-9. PubMed ID: 12942563 [Abstract] [Full Text] [Related]